Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute graft-versus-host disease after myeloablative HSCT; study terminated with pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation
• Myelodysplastic Syndromes

Drugs mentioned

• Efprezimod Alfa (CD24Fc)

Snippet

Sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Status: TERMINATED | Results posted: 2022-11-14